Transgene Reports First Quarter 2015 Financial Results
Business Wire - Wed Apr 22, 11:00AM CDT
Regulatory News:
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 48.71 (+0.04), NWBO: 8.12 (+0.07), ZIOP: 9.17 (-0.17), PCYC: 255.42 (-0.50), CVM: 0.84 (-0.03), PFE: 33.99 (+0.05), CLDX: 25.81 (+0.06), IMGN: 8.59 (+0.04), BMY: 67.64 (+0.19), RIGL: 4.09 (-0.11), INO: 7.97 (-0.02), KITE: 50.02 (-2.24), LH: 117.29 (-0.40), ABBV: 65.99 (+0.02), PBYI: 177.01 (+6.34)